Regatta Bio

Pre-clinical

Boston, United StatesFounded 2021regatta.bio

Regatta Bio develops engineered Treg cell therapies to treat chronic GvHD, transplant rejection, and autoimmune disease. Discover how we’re redefining immune tolerance.

Market Cap

Private

Pipeline

—

Patents

—

Publications

—

Private Company

Funding information not available

About

Regatta Bio develops engineered Treg cell therapies to treat chronic GvHD, transplant rejection, and autoimmune disease. Discover how we’re redefining immune tolerance.

Cell & Gene Therapy